3.4% in an observation unit to adults. Only 4.1% of the observations satisfied the French paediatric short-stay definition (patient in a bed monitored hourly). Compared to the clinicians' prognosticated rate, 1.3% less children were admitted as in-patients. CONCLUSIONS: Despite the absence of financial and regulatory frame in Belgium, observation is a frequent modality of care. Observation helped to refine diagnosis and treatments and to reduce in-patient admission rate. However, with regards to the French guidelines less than 5% could be qualified as paediatric A&E short-stay. Flexible observation units should be recommended.
PHP99 REIMBURSING TELEMONITORING IN EUROPE: ARE PAYERS READY?
Flostrand S 1 , Garde E 2 , Toumi M 3 1 Creativ-Ceutical, Paris, France, 2 Sanofi, Paris, France, 3 University Claude Bernard Lyon 1, Lyon, France OBJECTIVES: As evidence and experience of telemonitoring grows, health care payers are confronted with multiple challenges to reimburse these new healthcare solutions. This study evaluated the current reimbursement systems in five European markets (France, Germany, Italy, Spain, and the UK) to determine readiness for telemonitoring and to identify changes required to permit telemonitoring to develop in the future. METHODS: To identify current telemonitoring funding, we reviewed the sources and mechanisms used to pay for pilot projects, and then reviewed national and regional health care funding systems to evaluate the readiness to finance telemonitoring. RESULTS: There are important differences in financing telemonitoring among European countries. While pilots exist in all countries, these are financed on a project basis from European Union, national or regional funds, outside regular healthcare budgets. Budget silos, disease reference group (DRG) changes and contractual funding are key barriers to payer readiness for telemonitoring. In Germany, only one telemonitoring DRG act is defined, while in France and Italy, defining telemonitoring acts for reimbursement is underway. In these countries, payers are reluctant to pay for the monitoring and alert service component. In Spain, regional authorities are advancing pilots at different speeds but system reforms have not yet been undertaken. Only in the UK, the English NHS has moved from pilots to deployment through financing at the Primary Care Trust level. CONCLUSIONS: European reimbursement systems do not yet accommodate telemonitoring, and pilots and device purchases will not sustain this therapeutic solution. To enable telemonitoring, payers need to establish new codes and rules to pay for telemonitoring acts by health care professionals, and decide how to pay for the most complex element: the monitoring and alert service component. Options include: no reimbursement (the current option), a periodic fixed fee or capitation. Any option requires careful framing and the benefits of telemonitoring need further evaluation.
PHP100 DID IQWIG'S DRUG APPRAISALS IN CONNECTION WITH G-BA'S DIRECTIVES CHANGE PRESCRIBING BEHAVIOR OF GERMAN PHYSICIANS?
Valentin M 1 , Neises G 2 , Salek S 3 1 Fresenius University of Applied Science, Idstein, Germany, 2 ABDA, Berlin, Germany, 3 Cardiff University, Cardiff, UK OBJECTIVES: To assess the impact of different formats of G-BA's (Federal Joint Committee) directives had on the prescription behavior of health care professionals (HCPs) prior to the introduction of the AMNOG legislation (i.e. Directives restructuring the German pharmaceutical market). METHODS: A retrospective study of the IQWiG's (Institute for Quality and Efficiency in Healthcare) review of phar-maceutical products covered by a G-BA directive during a 5-year period (2005) (2006) (2007) (2008) (2009) (2010) ). An event list reporting the interaction of G-BA, IQWiG and BMG (German Minister of Health) was compiled by systematic searches of official websites. Regression analyses retrieved from IMS data bases (Intercontinental Marketing Services) were conducted defining a 95% confidence interval. Time points where actual sales exceeded or deceeded this confidence interval were reconciled with the list of events concluding if and what kind of events had impacted unit sales. RESULTS: G-BA required a mean of 1304 days to generate a directive followed by 567 days required by IQWiG to complete its review. IQWiG achieved a mean output of 15 projects per year, which is half of what NICE achieved in the same period. The format of the final directive had a strong influence on the overall review. These findings indicate that G-BA's directives did not influence the annual number of prescriptions during the five year period. CONCLUSIONS: The new set of laws -commonly known as AMNOG is targeting two important weaknesses of the previous systems, which are clearly identified by this study. Thus, clear ambitious timelines should be defined, especially for the most time consuming review stages, namely completion of the report plan and adherence to the principle of evidence based medicine for all reviews.
PHP101 BIOSIMILARS ARE NOT GENERICS FROM PAYER PERSPECTIVE
Shepelev J 1 , Rauland M 2 , Krattiger C 3 1 GfK HealthCare, London, UK, 2 GfK HealthCare, Nürnberg , Germany, 3 GfK Research Matters, Basel, Switzerland OBJECTIVES: To review the barriers and opportunities in market access for biosimilars. METHODS: Both primary & secondary research were used in this study. Primary research was conducted with payers, physicians, pharmaceuticals and biosimilar manufactures. RESULTS: The US and EU are currently the largest consumers of biologics in the world; however, other markets are expected to see strong growth in their use of biologics over the next few years. Although many biologics are expected to go off-patent in the next few years, (thereby creating an attractive opportunity for biosimilars); the complex structure of biologics makes the manufacturing process of biosimilars extremely difficult, and with EU legislation currently requiring phase I-III clinical trials to be conducted for all new biosimilars the developmental costs and barriers to entry of biosimilars are high. With respect to the costs per treatment, the price of biologics are significantly higher than for small molecules creating a use-limiting factor in many markets; for this reason biosimilars are recognised by payers and physicians as being cost-effective in the sense of being able to provide the same treatment but at a lower cost (20% cheaper). However, payers confirmed that cost-saving alone will not ensure access for biosimilars and physicians are hesitant to adopt biosimilars due to safety and efficacy concerns. CONCLUSIONS: With the use of biologics rapidly increasing, patent expiries expected to occur in the near future and the low numbers of competitors, companies are presented with a new and attractive market with the production of biosimilars. Although there are several challenges to entering the market (including the intense approval process) biosimilars are recognized and are treated differently from generics by payers. With drug costs increasing and concerns over the safety and efficacy of biosimilars, reduced costs of biosimilars together with clinical reassurance will enable broader acceptance and usage of biosimilars in most markets.
PHP102 BIOSIMILARS: PRICING & REIMBURSEMENT IN GERMANY: KEY INSIGHTS FROM SICKNESS FUNDS
Chaudhari SD, Bache B PAREXEL International, Uxbridge, Middlesex, UK OBJECTIVES: While the European biosimilars market is still in its infancy, these products are facing tough market access conditions and have yet to match the success of small-molecule generics. With the increasing cost consciousness of the payers and potentially safety concerns, it is imperative to explore the key pricing and reimbursement drivers and barriers for biosimilars from the payer-lens. In addition, the research aims to provide insights into strategies for their successful 'market access' in the German healthcare system. METHODS: This research was based on a combination of secondary and primary research to evaluate the key success factors for biosimilars. Secondary research of published data such as G-BA's assessment of biosimilars, current policies, sector-specific research articles contributed towards a framework to understand the key factors affecting payer's attitudes towards biosimilars, which was then validated through a telephone survey of 10 sickness funds in 2011. RESULTS: A multitude of factors determine price sustainability for biosimilars in Germany. The attitudes of sickness funds toward biosimilars vary, which affect price dynamics as well as the cost containment measures to encourage/ inhibits its use. While the use and prescribing of biosimilars are subject to quotas and guidelines encouraging its use, some sickness funds' focus on price is moderated by concerns about the safety of biosimilars. Overall, in order to provide access to these products, payers are increasingly raising data requirements. CONCLUSIONS: There exits significant inter-payer variability in the extent of inter-changeability and data expectation from future biosimilars. Payer expectations vary, based on the stage of the disease/ indications, the level of unmet need, and the number of available alternatives. In a climate of increasing pricing concerns, securing marketing approval is no longer the end of the road for biosimilars. Hence, unlike generics, biosimilars cannot be merely 'sold' but need to be 'marketed'.
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